What is SYMQY stock price today?

SYMQY (SymBio Pharmaceuticals Limited) stock is trading at $0.56 as of the latest market data. Stock prices update in real-time during market hours (9:30 AM - 4:00 PM ET).

Is SYMQY stock going up or down today?

SYMQY stock price movements are influenced by market conditions, news, earnings reports, and investor sentiment. Check our live dashboard for real-time price changes and technical indicators.

Should I buy SYMQY stock now?

The decision to buy SYMQY depends on your investment strategy, risk tolerance, and financial goals. Our AI analysis evaluates fundamentals, valuation metrics, growth prospects, and market conditions to help inform your decision.

Is SYMQY a buy, hold, or sell right now?

Our AI-powered analysis provides buy/hold/sell recommendations for SYMQY based on multiple factors including valuation, growth metrics, technical indicators, and analyst consensus. Visit our dashboard for the latest recommendation.

Is SYMQY stock overvalued or undervalued?

Use our DCF valuation calculator to determine if SYMQY is overvalued or undervalued based on fundamental analysis and future cash flow projections.

What is SYMQY's P/E ratio?

P/E ratio data for SYMQY will be available after the company reports earnings. Visit our dashboard for the latest financial metrics.

What is SYMQY's market cap?

SYMQY (SymBio Pharmaceuticals Limited) has a market capitalization of $0.03 billion, making it a small-cap stock.

What is SYMQY's price to book ratio?

SYMQY trades at a price-to-book (P/B) ratio of 2.74, which compares the stock price to the company's book value per share. A P/B below 1.0 may indicate undervaluation, while above 3.0 may suggest premium pricing.

Does SYMQY pay dividends?

SYMQY does not currently pay dividends. Many growth companies reinvest profits into the business rather than paying dividends.

What is SYMQY's dividend yield?

SYMQY does not currently pay dividends or dividend data is not available. Check our dashboard for the latest information.

Is SYMQY stock a good long-term investment?

SYMQY's long-term investment potential depends on sustainable competitive advantages, revenue growth, profitability, management quality, and industry dynamics. Our AI analysis evaluates these factors to assess long-term prospects.

What is SYMQY's revenue growth rate?

SYMQY has shown revenue growth of -0.4% over recent periods. Consistent revenue growth is a key indicator of business health and competitive positioning.

Profitability metrics for SYMQY are available on our dashboard with complete income statement analysis.

What are the risks of investing in SYMQY?

Key risks for SYMQY include market volatility, competitive pressures, regulatory changes, economic conditions, execution risks, and company-specific factors. Our AI analysis identifies material risks and their potential impact on valuation.

How does SYMQY compare to its competitors?

Compare SYMQY to industry peers on our dashboard using metrics like P/E ratio, revenue growth, profit margins, market share, and valuation multiples. Competitive analysis helps contextualize SYMQY's performance and positioning.

What is SYMQY's stock price target for 2026?

Our AI model provides price targets for SYMQY based on fundamental analysis: Bull case $0.73 (+30%), Base case $0.64 (+15%), Bear case $0.50 (-10%). Visit our prediction page for detailed forecasts.

What do analysts say about SYMQY?

Wall Street analysts provide ratings (buy/hold/sell) and price targets for SYMQY. Our dashboard aggregates analyst consensus, target prices, and recent upgrades/downgrades to help you understand professional sentiment.

When is SYMQY's next earnings report?

SYMQY reports earnings quarterly. Check our dashboard for the upcoming earnings date, analyst estimates for revenue and EPS, and historical earnings performance. Earnings reports often drive significant stock price movements.

SYMQY - SymBio Pharmaceuticals Limited

NYSE * Healthcare * Drug Manufacturers - Specialty & Generic

$0.56

+$0.00 (+0.00%)

About SymBio Pharmaceuticals Limited

SymBio Pharmaceuticals Limited engages in the and development, manufacturing and sales of pharmaceuticals and other related operations in Japan and internationally. It offers SyB V-1901, an antiviral drug for post-transplant infections, blood cancers and solid tumors, and neurodegenerative diseases; SyB L-1701, an RTD liquid formulation; SyB L-1702, an RI administration under the TREAKISYM name; and C-1101, an antiviral drug BCV injectable and oral formulations against double-stranded DNA viruses. The company was incorporated in 2005 and is based in Minato, Japan.

SYMQY Key Statistics

Market Cap

$27.21M

P/B Ratio

2.74

EPS

$-0.61

Revenue Growth

-0.4%

Employees

108

How SYMQY Compares to Peers

SYMQY is the smallest among peers, which may offer higher growth potential

P/E Rank

N/A

of 5

Margin Rank

N/A

of 5

Growth Rank

of 6

Size Rank

of 6

Company	Market Cap	P/E	Growth	Margin	Compare
SYMQY(This stock)	$27.21M	N/A	-0%	0.0%	-
LLYEli Lilly	$809.09B	39.3	0%	0.3%	vs LLY
JNJJohnson &	$575.17B	21.8	0%	0.2%	vs JNJ
PFEPfizer Inc	$154.84B	20.0	-0%	0.1%	vs PFE
MRKMerck &	$291.50B	16.2	0%	0.3%	vs MRK
ABBVAbbvie Inc	$369.65B	88.6	0%	0.1%	vs ABBV

SymBio Pharmaceuticals Limited Company Information

Headquarters: Toranomon Towers Office, Minato, Japan, 105-0001, undefined
Website: www.symbiopharma.com
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Data Updated: April 17, 2026 at 8:38 PM EDT

Ready to invest in SYMQY?

Commission-free trading available. Affiliate links.

Upcoming Events for SYMQY

Dashboard

Enter a ticker to analyze